Overview

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Ipsen
Treatments:
Dopamine
Somatostatin